Skip to content

    Vinati Organics

    VINATIORGAGood
    Chemicals·12 Feb 2024
    Management Summary

    Vinati Organics reported a resilient Q3 FY24, characterized by margin expansion despite a slight sequential revenue dip, primarily due to the successful amalgamation with Veeral Additives. Management signaled the end of the global de-stocking phase in its core ATBS segment and is pivoting towards aggressive growth in antioxidants and new specialty chemical niches. The company is maintaining a heavy capex cycle to double its revenue over the next 4-5 years while sustaining healthy 25-27% EBITDA margins.

    Highlights

    8

    • Total Income for Q3 FY24 stood at ₹457 crores on a merged basis, a 4% decline QoQ.

    • EBITDA increased by 7% QoQ to ₹124 crores, with margins expanding from 24% to 27%.

    • Profit After Tax (PAT) rose 6% QoQ to ₹77 crores.

    • ATBS expansion to 60,000 MT is on track for completion by December 2024.

    • Antioxidant revenue target set at ₹250 crores for FY25, doubling from FY24 levels.

    • Management expects a 15% to 20% revenue CAGR over the next three years.

    • New MEHQ & Guaiacol plant (VOPL) expected to be commissioned by March 2024.

    • Company remains debt-free with no long-term debt or working capital loans.

    What Changed1

    vs Q4 FY24

    Guidance items5 → 6 (+1)

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹457 Cr-4%QoQ
    2. 02EBITDA₹124 Cr+7.0%QoQ
    3. 03EBITDA Margin27%
    4. 04PAT₹77 Cr+6%QoQ

    Segment breakdown

    Product Revenue Mix (Q3 FY24)
    30% ATBS20% IBB20% Butylphenols & IB Derivatives10% Isobutylene20% Antioxidants & Others
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Revenue CAGR
    15% to 20%
    		Medium
    Revenue
    Total Revenue
    ₹3,000 crores
    		Medium
    Revenue
    Antioxidant Revenue
    ₹250 crores
    		High
    Margin
    EBITDA Margin
    25% to 27%
    		High
    Capacity
    ATBS Capacity
    60,000 tonnes
    		High
    Capex
    FY25 Capex
    ₹450-500 crores
    		High

    Risks & concerns

    4
    RiskSeverity

    Global Antioxidant Market Weakness

    The antioxidant market worldwide has seen demand weakness for 15-18 months, leading to low capacity utilization (currently 25%). — Management acknowledged

    medium

    Raw Material Price Volatility

    Margins are sensitive to input prices; low raw material prices inflate margins, while high prices compress them. — Management acknowledged

    medium

    Project Commissioning Delays

    ATBS expansion was delayed due to market conditions, and some VOPL projects face longer lead times for equipment. — Analyst acknowledged

    low

    Areas of Evasion(1)

    • Specific details on competitor capacity additions in ATBS were redirected to 'market research'.

    Q&A highlights

    3

    “Prior to the merger... this INR300 crores was booked as a loan... So, that entire amount of INR32 crores gets knocked off in the last two years of interest income... Secondly, the depreciation... is also adding to about INR15 crores per year.”

    Explains why the merger initially appeared margin-dilutive due to the loss of interest income and increased depreciation, despite operational synergies.

    asked by Surya Patra

    2 min read5 chapters

    Detailed Narrative

    01

    Amalgamation with Veeral Additives

    The NCLT sanctioned the merger with Veeral Additives Private Limited (VAPL) effective April 1, 2021. This led to a restatement of financials, showing a Q3 FY24 total income of ₹457 crores. While the merger initially impacted margins due to the elimination of ₹32 crores in annual interest income and an additional ₹15 crores in depreciation, management expects it to become 'value-attractive' within six months as capacity utilization improves from the current 25%.

    02

    ATBS Recovery and Expansion

    Management believes the global de-stocking effect in ATBS is nearly over, with sales picking up in February 2024. The company is expanding ATBS capacity from 40,000 MT to 60,000 MT, with commissioning expected by December 2024. For FY25, management anticipates ATBS volumes to be at least 30% higher than FY24 levels, supported by long-term contracts and a 65% global market share.

    03

    Antioxidant Business Growth Trajectory

    Despite a weak global market for antioxidants over the last 18 months, Vinati Organics expects to double its revenue from this segment to ₹250 crores in FY25. The company's competitive advantage stems from double backward integration into butyl phenols and isobutylene. They aim to reach full capacity utilization of their 24,000 MT plant within 2-3 years, targeting both domestic (8,000 MT) and export (16,000 MT) markets.

    04

    VOPL and New Product Pipeline

    The 100% subsidiary, Veeral Organics Private Limited (VOPL), is executing a ₹480 crore capex plan for niche specialty chemicals. The MEHQ and Guaiacol plant (2,000 MT and 1,000 MT respectively) is set for a March 2024 commissioning. Other products like isoamylene derivatives, 4-MAP, and Anisole are scheduled for the second half of FY25. These projects are expected to deliver a 15-20% ROI with a 1:1 asset turnover ratio.

    05

    Margin Sustainability and Pricing Strategy

    Management clarified that the historical 30% EBITDA margins were 'golden periods' and not sustainable long-term. They have guided for a sustainable blended margin of 25% to 27%. Current margin improvements are attributed to declining raw material prices being passed through, while the company maintains its pricing power through long-term contracts and dominant market positions in core products like ATBS and IBB.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.